Jazz Pharmaceuticals and AbCellera announced a collaboration to discover next-generation T-cell engaging multispecific antibodies, with Jazz paying $56 million upfront and eligible for up to $792 million in milestone payments per program. The partnership expands Jazz's oncology focus on gastrointestinal cancers while providing AbCellera meaningful upfront and milestone revenue.